

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A therapeutic composition comprising a first agent that targets an interleukin-15 receptor (IL-15R) and a second agent that targets an interleukin-2 receptor (IL-2R), wherein the first agent comprises a mutant IL-15 polypeptide that ~~binds an IL-15R but fails to fully activate signal transduction through the IL-15R, has a substitution of aspartate for glutamine at positions 149 and 156 of SEQ ID NO:4,~~ the mutant IL-15 polypeptide being optionally fused to the Fc region of an immunoglobulin, and the second agent comprises an IL-2 polypeptide that binds an IL-2R, wherein the IL-2 polypeptide ~~being optionally is~~ fused to the Fc region of an immunoglobulin.

2-34. (Canceled)

35. (Previously presented) The therapeutic composition of claim 1, wherein the mutant IL-15 polypeptide binds an IL-15R α subunit of an IL-15R.

36. (Previously presented) The therapeutic composition of claim 1, wherein the immunoglobulin is an immunoglobulin of the G class (an IgG).

37-41. (Canceled)

42. (Previously presented) The therapeutic composition of claim 1, further comprising rapamycin.

43. (Currently amended) The therapeutic composition of claim 1, wherein the mutant IL-15 polypeptide is at least [[90%]] 95% identical to wild-type IL-15.

44. (Previously presented) The therapeutic composition of claim 1, wherein the Fc region of an immunoglobulin, when present and fused to the mutant IL-15 polypeptide or the IL-2 polypeptide, is a target-cell depleting Fc region.

45. (Previously presented) A therapeutic composition comprising a first agent that targets an interleukin-15 receptor (IL-15R) and a second agent that targets an interleukin-2 receptor (IL-2R), wherein the first agent consists of a mutant IL-15 polypeptide that is fused to the Fc region of an immunoglobulin, wherein the mutant IL-15 polypeptide has a substitution of aspartate for glutamine at positions 149 and 156 of SEQ ID NO:4, binds an IL-15R but fails to fully activate signal transduction through the IL-15R, the mutant IL-15 polypeptide being optionally fused to the Fc region of an immunoglobulin, and the second agent consists of an IL-2 polypeptide that binds an IL-2R, ~~the IL-2 polypeptide being optionally~~ and is fused to the Fc region of an immunoglobulin.

46. (Canceled)

47. (New) The therapeutic composition of claim 45, wherein the mutant IL-15 polypeptide binds an IL-15R α subunit of an IL-15R.

48. (New) The therapeutic composition of claim 45, wherein the immunoglobulin is an immunoglobulin of the G class (an IgG).

49. (New) The therapeutic composition of claim 45, further comprising rapamycin.

50. (New) The therapeutic composition of claim 45, wherein the mutant IL-15 polypeptide is at least 95% identical to wild-type IL-15.

51. (New) The therapeutic composition of claim 45, wherein the Fc region fused to the mutant IL-15 polypeptide or the Fc region fused to the IL-2 polypeptide, is a target-cell depleting Fc region.